

HHCS Cryopreserved Human Hepatocytes for Suspension Assays Cell Specification – Certificate of Analysis (CoA)								
Lot HH130614-1				Batch Release: Sept 28, 2020				
Species: Human			Gender: male		Age: 53 years			
			Size: 191 cm		Weight: 90 kg			
			Non-Smoker					
Serology: HAV, HBV, HCV, HIV 1/2: negative			Diagnosis: liver metastasis in left lobe					
Medical History: Chemotherapy (Folfox 4 protocol) until 03/2012)			Therapy: liver resection					
Medication: Fragmin P forte								
Cryopreservation:			Thawing: n=5					
Date:		June 14, 2013		Post-thaw viability: 74.5 ± 11.1 %				
Amount per vial:		15.0 x 10 ⁶ cells		Post-thaw yield per vial: 7.3 ± 0.5 x 10 ⁶ cells				
			Recovery: 49 ± 3 %					
Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10 ⁶ cells in 0.5 ml HPM-Cryo):								
Time (h)	0	0.5	1	1.5	2	3	4	5
Viability (%)	86.6	71.7	76.0	72.5	71.4	70.0	71.4	60.0
Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.								
Store at -150 °C or in the vapour phase of LN₂								
This product should be considered as potential biohazard. Only intended for <i>in vitro</i> use.								
Issued by A. Ullrich				Verified by C. Garve				